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1. Abstract 
 
Objectives: To compare the cardiovascular and metabolic outcomes of Insulin versus non-
insulin glucose lowering therapy (GLT). 
Methods: We included randomised control trials (RCTs) which randomised patients aged 
>18 years with Type 2 Diabetes (T2D) to insulin vs non-insulin GLT. We used risk ratios (RR), 
risk difference (RD) and odds ratios (OR) with 95% confidence interval (95%CI) to analyse 
the treatment effects of dichotomous outcomes and mean differences (with 95% CI) for 
continuous outcomes.  
Results: We included 18 RCTs with 19,300 participants. There was no significant difference 
in the risk of all-cause mortality and CV events between the groups (RR= 1.01; 95%CI: 0.96 - 
1.06; p = 0.69). In 16 trials, insulin showed greater efficacy in glycaemic control (mean diff= -
0.20; 95%CI: -0.28 to -0.11 but the proportion achieving HbA1c level of either ≤7.0% or 7.4% 
(53 or 57mmol/mol) was similar in both (OR=1.55; 95%CI= 0.92 to 2.62). The non-insulin 
group had a significant reduction in weight (mean diff = -3.41; 95%CI: -4.50 to -2.32) and an 
increase in the proportion of adverse events (54.7% vs 45.3%, p= 0.044), but the insulin 
group showed an (RR= 1.90; 95%CI: 1.44 to 2.51) increased risk of hypoglycaemia.   
Conclusion: There was no difference in the risk of all-cause mortality and adverse 
cardiovascular (CV) events between Insulin and non-insulin GLTs. Insulin was associated 
with superior reduction in HbA1c; least reduction in weight and higher risk of 
hypoglycaemia. Both showed similar proportion of patients achieving HbA1c target. Non-
insulin GLTs were associated with a higher risk in reported adverse drug events. 
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2. Introduction:  
For many patients with type 2 diabetes (T2D), treatment intensification using additional 
antihyperglycaemic agents is required in order to achieve optimal glycaemic control and 
prevent long-term vascular complications.[1, 2] A variety of antihyperglycaemic agents are 
available but questions regarding the long term safety and efficacy of some of these agents 
have been raised. In addition, recent focus by international regulatory agencies on the 
cardiovascular (CV) safety profile of commonly used antihyperglycaemic agents[3, 4] have 
led to debate about the most appropriate choice of therapy for treatment intensification.  
Amidst this, exogenous insulin remains to be one of the most established glucose lowering 
therapies available[5-10] and its use in people with T2D has grown markedly over recent 
years.  More recently however, the effectiveness and safety of insulin therapy has been a 
subject of intense discussion.[11-13] Moreover, recent large epidemiological studies have 
reported adverse cardiovascular CV outcome and increase mortality with insulin compared 
with non-insulin therapy.[13, 14] While the possible mechanism behind the observed the 
association between insulin and adverse cardiovascular and metabolic outcomes and 
mortality remains unclear, it is hypothesized that these may include, but not limited to, 
hypoglycaemia and weight gain. Although insulin therapy is associated with HbA1c lowering, 
weight gain and increased risk of hypoglycaemia, comparative analysis between insulin and 
non-insulin anti-diabetic therapy on these parameters are currently not available. A 
systematic review of RCT on the CV safety of insulin compared with non-insulin therapy has 
also not been reported.  Thus, despite extensive experience of the use of insulin in routine 
clinical practice, we contend that the safety and efficacy of insulin has not been subjected 
to similar scrutiny in an adequately powered RCT setting, as is currently required for new 
antihyperglycaemic agents.[3] 
We therefore aimed to compare the benefits and harms of Insulin versus non-insulin 
glucose lowering therapy (GLT) as reported in RCT involving patients with T2D. 
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3. Methods: 
3.1. Search Strategy:  
 
We searched the following electronic databases from January, 2005 to December, 2014: The 
Cochrane Library, Ovid MEDLINE, EMBASE, and International Pharmaceutical Abstracts. We 
also scanned the reference lists of the included clinical trials for studies that met our 
inclusion criteria. The search terms used are in Figure 1 of the Appendix. 
3.2. Study selection: 
Two authors (UA and JM) searched and screened the titles of all studies to assess their 
relevance to this study in line with the inclusion criteria. Clinical trials were included if they 
were randomised; involved only adult (18 years and above) patients with type 2 diabetes; 
compared insulin with any non-insulin GLT irrespective of baseline GLT (so far as the only 
difference between both groups is insulin); reported clinical outcomes as all-cause mortality, 
cardiovascular (CV) events (Myocardial infarction, stroke, heart failure, and CV mortality) 
and metabolic outcomes (e.g. glycaemic control, change in weight, and events of  
hypoglycaemia);  had an intervention period of at least 24 weeks; and conducted within the 
past ten years (2005-2014). The last two decades have witnessed unprecedented 
advancement in diabetes care and management with the emergence of newer antidiabetic 
agents. So, the last decade was chosen to reflect current trends in diabetes care and provide 
recent evidence that will further guide diabetes management. We used only published trials 
and restricted the language to only English language. 
Abstracts of the selected studies were then retrieved and reviewed thoroughly for inclusion 
in line with the inclusion criteria. The full text copies of the trials that met the inclusion 
criteria were then retrieved. Studies in persons with type 1 diabetes; without a clear 
protocol; with mixed age groups; no clear drug-combinations or short follow-up duration 
(<24 weeks) were excluded. A period of 24 weeks has been shown to be adequate to 
explore the effect of the treatment on the study outcomes.[15, 16] 
The finally selected studies were imported into Endnote referencing software[17] where 
duplicates from the different databases were removed. The flow chart graphically explains 
the pathway to the selection of studies (Figure 1).  
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3.3. Data Extraction and Risk of bias assessment: 
 Independently, two authors (UA and JM) extracted data from the 18 selected studies which 
met our inclusion criteria into a self-designed record form. These included basic study 
characteristics as number of participants, gender, patients’ description, characteristics of 
the trials, follow-up and outcome measures. 
Using the Cochrane Handbook for Systematic Reviews of Interventions tool,[18] the authors 
independently assessed the risk of bias and quality of each included trial according to the 
following domains: allocation sequence, allocation concealment, blinding (of participants, 
personnel and outcome assessors), incomplete outcome data, and selective outcome 
reporting and other sources of bias as funding of trials and drug quality. The trials were 
classified as low, high or unclear risk of bias. 
The primary outcomes were  
i. All-cause mortality and 
ii. CV events (defined as CV mortality, non-fatal myocardial infarction (MI), non-fatal 
stroke and heart failure).  
 
The secondary outcomes were  
i. Metabolic outcomes as glycaemic control (defined by the mean reduction in HbA1c 
and the proportion of patients attaining a target HbA1c level); and mean reduction in 
weight. 
ii. Episodes of hypoglycaemia and  
iii. The number of reported adverse drug events. 
 
3.4. Statistical Analyses: 
The extracted data were entered into Microsoft excel document and exported into The 
Review Manager Software version 5.3 which we used for all statistical analyses.  For 
continuous outcomes (changes in HbA1c and weight), we computed the mean differences 
between both treatment groups. In doing this, we entered the actual mean differences in 
our analyses where these were provided in the trials and where not available, we computed 
the mean differences from the mean values recorded in the included trials.  
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Q-test and I2 statistics were used to test for heterogeneity between the trials. A cut off of I2 
≥ 50% was used to define heterogeneity. Where I2 > 50%, the random model was used and 
where there is no significant heterogeneity, the fixed model was used.[18] 
We used Risk Ratios (RR) or Odds Ratios (OR) with 95% confidence interval (95%CI) as the 
summary statistics for dichotomous variables (All-cause mortality; CV-outcomes; proportion 
of participants attaining the target HbA1c levels; and risk of hypoglycaemia; and number of 
reported adverse events).These were derived from the number of events and the total 
number of participants in each treatment group. For continuous variables, weighted mean 
difference and 95% CI was used to summarise the data. Studies with missing data for any 
outcome were not included in the meta-analyses.  
We performed subgroup analyses for the secondary outcomes of mean reduction in HbA1c 
and weight to assess if there are significant differences in the estimates based on according 
to the class of drugs in the non-insulin arm using a test of interaction. We tested for 
interaction according to risk of bias. Also, we used the funnel plot and Egger’s test to detect 
the possibility of publication bias in the included trials in our meta-analysis.  
 
All results were presented in tables, flow chart, forest plots, funnel plots, and bias tables.  
The review protocol was registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) 
with the registration number CRD42015024559. The subgroup analysis for weight and 
addition of a secondary outcome of reported adverse events were not captured in our 
original protocol.  
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4. Results: 
4.1. Literature Search Results: 
From the electronic searches, we identified 2,445 papers from the databases (Figure 1). 
Following the exclusion of duplicate reports and review of the titles, 2,172 were dropped. 
After abstraction, 28 citations were selected and their full papers retrieved. Further 10 
studies were removed because two had no clearly defined intervention and comparator 
groups, one was published in Danish; another involved people with both type 1 and 2 
diabetes while one was amongst cystic fibrosis patients; two were single arm and/or non-
randomised; another had more than two comparator arms; one study compared different 
types of insulin versus altering insulin doses; another measured quality of life (QOL) as its 
outcome. 
Though the ORIGIN trial was not very clear on the specific drugs in its  standard care 
arm,[19] this large trial which explore CV risks was included in our meta-analysis based on 
the consistency of the use of Insulin Glargine in  its insulin arm and to a large extent, the 
high probability of not including insulin in its standard care arm. Similarly, though DIGAMI-2 
trial[20] had three arms, it was chosen the insulin and non-insulin arms were clearly defined 
and outcomes compared between these two.  Finally, 18 clinical trials[15, 16, 19-34] were 
selected for meta-analysis (Figure 1). 
 
4.2. Baseline Characteristics: 
 A total of 19,300 participants were involved in the selected 18 RCTs in which 9476 were 
randomised to insulin and 9351 to non-insulin GLT. Table 1 describes the baseline pre-trial 
characteristics of the trial participants. Majority (68.8%) of these trials compared insulin 
with GLP-1 (mostly exenatide), other comparators were DPP-4 inhibitors (12.5%), 
thiazolidinediones (12.5%) and metformin (6.2%). Insulin glargine was used in 12 (68.8%) 
trials while Insulin NPH, lispro and degludec were used in one trial each. Eight trials 
compared Insulin glargine and Exenatide.[21, 22, 24-27, 30, 31]  The trial duration ranged 
from 24 weeks to 6.2 years. The mean age range of participants was 53.6 to 61.2 years. Also, 
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the mean baseline HbA1c range was 7.6 to 9.7%; BMI: 28.8 – 34.1kg/m2; and diabetes 
duration: 4.5 to 11.5 years (Table 1). 
In Table 2, the specific details of the trials- the treatment arms and a few outcome measures 
of interest- were highlighted 
4.3. Bias Risk Assessment: 
All the trials showed high risk of performance and detection bias. This is because all the 
trials were open-label with no blinding of participants and assessors except only one trial 
which reported blinding of assessors[27]. Conversely, the risk of selection bias was low for 
all trials except one pilot study[29] in which no random sequence was generated nor 
allocation concealed. The risk of attrition, reporting and academic biases were low in all the 
included trials (Figure 2, Appendix).  
 
4.4. All-Cause Mortality and Cardiovascular (CV) Events: 
The primary outcomes of all-cause mortality and CV events were only reported by two trials 
involving a total of 13,317 participants in which 6738 were randomised to insulin and 6579 
to the non-insulin arm (Figure 2). We found no significant heterogeneity between the 
studies for any of these outcomes (x2 = 3.53, p = 0.47, I2 = 0%). A total of 5,546 composite 
events were reported (2836 vs 2710). There was no significant difference in the risk of All-
cause mortality and CV events between both treatment groups (RR= 1.01; 95%CI: 0.96 - 
1.06; p = 0.69). 
4.4.1. Risk of All-Cause Mortality:  
A total of 2,158 all-cause deaths occurred in the two included trials (1104 vs 1054). There 
was an equal risk of all-cause mortality between the two treatment arms (RR= 1.00; 95%CI: 
0.93 - 1.08; p = 0.97) (Figure 2). 
4.4.2. Risk of Cardiovascular Events:  
In Figure 2, our meta-analysis showed no significant difference in the risk of cardiovascular 
deaths in both treatment arms in the two trials which reported CV deaths (n= 1319; RR= 
1.02; 95%CI: 0.92 - 1.13; p = 0.65). There was no heterogeneity among these studies (p= 
0.69). A total of 735 events of non-fatal myocardial infarction were reported with a risk ratio 
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of 1.07 (95%CI: 0.93 – 1.24; p = 0.32). Similarly, no significant difference was observed in the 
risk of non-fatal stroke (n = 663; RR= 1.04; 95%CI: 0.90 - 1.21; p = 0.56) and heart failure (n= 
671; RR= 0.90; 95%CI: 0.77 - 1.04; p = 0.15).  We could not detect any evidence of 
publication bias in these trials in the meta-analysis for the risk of CV events. The funnel plot 
(Figure 3a, Appendix) and the Egger’s test to detect any asymmetry in the funnel plot 
yielded no significant finding (p-value = 0.285). 
 
4.5. Glycaemic Control: 
4.5.1. Mean Changes in HbA1c level: 
Only 16 of the 18 trials (N= 5201) reported mean changes in HbA1c in both treatment 
groups. Of these, three trials[22, 25, 33] reported only the mean changes in each arm. So, 
we computed the mean difference between both treatment groups, using the mean 
difference of each arm. Overall, insulin showed greater efficacy in glycaemic control 
compared to non-insulin GLTs (n=5201, mean difference= -0.20; 95%CI: -0.28 to -0.11; 
heterogeneity I2= 88%; p<0.00001) (figure 2). Tests of interaction showed no significant 
difference between the trials based on the risk of bias (p= 0.61). 
Figure 3 shows the comparison between insulin and different drug groups in then non-
insulin arm. There was a significant heterogeneity between the subgroups. 
Tests of interactions showed significant subgroup differences according to the drug groups 
in the non-insulin arm (I2 = 84.3%; p = 0.0003). With the GLP-1 analogues, 11 trials, involving 
1,796 and 1,821 participants in the insulin and GLP-1 arms respectively, showed that insulin 
was associated greater glycaemic efficacy (n=3,617 mean difference= -0.13; 95%CI: -0.21 to -
0.05; heterogeneity I2= 79%; p<0.001) compared to GLP-1 analogues.  Only two trials with a 
total of 247 participants compared the Thiazolidinediones (127) with Insulin (120). The two 
trials showed no heterogeneity between them (p=0.57). Insulin showed greater glycaemic 
efficacy compared to the TZDs (n=247, mean difference= -0.17; 95%CI: -0.30 to -0.05; 
heterogeneity I2= 0%; p<0.007). Two trials compared the DPP4 inhibitors with insulin. 
Compared to DPP4 inhibitors, insulin showed greater reduction in HbA1c (n=452, mean 
difference= -0.52; 95%CI: -0.67 to -0.36; heterogeneity I2= 34%; p<0.00001). One trial 
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compared biguanides (metformin) to insulin and showed the superiority of insulin in 
glycaemic control (n=214, mean difference= -0.22; 95%CI: -0.39 to -0.05; p = 0.01). 
4.5.2. Proportion achieving a target HbA1c level: 
Ten trials with a total of 4,107 participants reported the proportion of patients achieving a 
target HbA1c level. In nine, the target was 7.0% (53mmol/mol) while one[25] had 7.4% 
(57mmol/mol) as its target. The included trials showed a significant heterogeneity (I2 = 93%, 
p <0.00001) but showed no significant difference between insulin and non-insulin groups in 
achieving a glycaemic control level of ≤ 7.5% (n= 4107; OR= 1.55; 95%CI = 0.92 to 2.62; 
Heterogeneity I2 =93%; p=0.10) (Figure 4, Appendix). 
 
4.6. Changes in Weight: 
A total of 16 trials with 17,795 participants reported mean changes in weight. One trial[29] 
reported mean change in BMI and was excluded in this meta-analysis. The non-insulin group 
had a significant reduction in weight from baseline to the endpoint than the insulin group 
(n= 17,795; mean diff = -3.41; 95%CI: -4.50 to -2.32; Heterogeneity I2 = 100%; p < 0.0001).  
There was a significant interaction between the subgroups of the non-insulin (p < 0.00001). 
We observed a significant mean weight reduction of 4.23kg in the GLP-1 analogues 
compared to insulin (n= 3704, mean diff = -4.23; 95%CI: -4.79 to -3.67; Heterogeneity I2 = 
90%; p < 0.00001). In the only trial involving the TZDs, insulin showed a mean reduction of 
1.4kg in weight compared to rosiglitazone (n= 217; mean diff: 1.40; 95% CI: 1.29 to -1.51; p 
< 0.00001). On the contrary, the DPP4 inhibitors showed a significant reduction in weight 
(n=927; mean diff = -2.10; 95%CI: -3.31 to -0.89; Heterogeneity I2 = 100%; p = 0.0007) 
compared to insulin; while the metformin group showed a mean weight reduction of 0.1kg 
compared to a mean weight gain of 3kg by the inhaled insulin- Exubera (n= 410; mean diff = 
-3.14; 95%CI -3.71 to -2.57; p < 0.00001). Finally, the standard care arm of the ORIGIN trial 
showed a mean weight reduction of 2.10kg compared to the insulin glargine arm (n= 
12,537; mean diff: -2.10; 95%CI: -2.11 to -2.09; p < 0.00001 as shown in Figure 4. 
 
 
 
11 | P a g e  
 
4.7. Hypoglycaemia events: 
The pattern of reporting hypoglycaemia differed among the trials and this made it difficult 
for the reports of five trials to be included in the meta-analysis. Most trials defined it as an 
event characterised by simple symptoms as sweating, palpitations, hunger pangs and 
lethargy irrespective of confirmatory blood glucose less than 4.0mmol/L. For this meta-
analysis, we defined severe hypoglycaemia as that which may necessitate assistance from 
another person; or associated with recovery after oral carbohydrate, glucagon or glucose 
administration; or with blood glucose less than 2.0mmol/L. 
Figure 5 shows the proportion of adverse treatment effect represented by the events of 
hypoglycaemia as reported in 12 of the trials comprising 16,143 participants. There was 
almost a two-fold increased risk of hypoglycaemia in the participants on insulin therapy 
compared to those on non-insulin therapy (RR= 1.90; 95%CI: 1.44 to 2.51; Heterogeneity I2 = 
91%; p = 0.0001).  
 
4.8. Reported adverse events: 
There were variations in the pattern, proportions, measures and number of adverse events 
reported in the different trials. These were either reported as the proportion of people with 
adverse drug-related events, and/or number of reported adverse events. One trial did not 
report any adverse event.[29] The overall proportion of reported adverse drug-related 
events was slightly higher in the non-insulin than in the insulin group (54.7% vs 45.3%, p= 
0.044) 
In the insulin group, the most reported adverse event was nasopharyngitis (21.08%) 
compared to nausea (42.71%) in the non-insulin group. Other common symptoms 
associated with insulin groups are headache (13.76%), diarrhoea (8.73%), influenza (6.0%), 
and cough (5.38%) while nasopharyngitis (17.93%), diarrhoea (16.69%), headache (14.72%), 
vomiting (12.9%) and gastrointestinal pain (7.87%) were most commonly reported in the 
non-insulin group (Table 3). 
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Only 12 trials with 2414 and 2363 participants in the non-insulin and insulin groups 
respectively reported the number of those with adverse drug-related events which we 
included in the meta-analysis (Figure 6). The non-insulin arm had 13 additional people per 
100 with adverse drug-related, compared to the insulin arm (Risk diff = 0.13; 95%CI = 0.05 – 
0.21; Heterogeneity I2 = 91%; p = 0.002). The fixed effect model showed no significant 
difference between both treatment groups (p= 0.236). 
 
 
5. Discussion: 
This meta-analysis involving 18 trials with 19,300 participants compared CV and metabolic 
outcomes between insulin and non-insulin GLTs in adult patients with type 2 diabetes. Data 
for meta-analysis for CV outcomes were provided by only 2 trials involving 13,317 
participants and showed no difference in the risk of all-cause mortality; cardiovascular 
deaths, non-fatal MI, non-fatal stroke, heart failure and a composite of these events in the 
insulin vs non-insulin treatment groups. Insulin showed superior efficacy in glycaemic 
control; while the non-insulin treatment arm consistently showed a reduction in weight. The 
risk of hypoglycaemia increased almost 2-folds with insulin, while adverse events were 
slightly significantly higher in the non-insulin arm. 
 All the included trials lasted for more than 24 weeks, which in our view was sufficient to 
establish a biological plausibility between these GLTs and the outcomes of interest. All trials 
had a low-risk of bias and this helped to mitigate the risk of overestimation of benefits and 
underestimation of risks associated with trials with high risk of bias.[35] 
The DIGAMI-2 trial population was drawn from patients with clinically diagnosed diabetes, 
and established CV risk. We pooled and compared data from only two arms (insulin vs non-
insulin GLTs) of the three-arm trial.[20]  In the ORIGIN trial,[19] the population comprised 
both established cases of diabetes; people with impaired fasting plasma glucose and 
impaired glucose tolerance. Both trials involved patients who were at very high risk of 
cardiovascular event.  Similarly, all the data were used in our analysis with the standard care 
arm (defined as any GLT apart from insulin glargine, based on the investigators’ best 
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judgement and prevailing local guidelines), used as the non-insulin arm of our analysis. 
Whilst this trial did not report any CV outcome specifically for people with established case 
of diabetes, we nonetheless used both in our meta-analysis. In addition, the ORIGIN trial’s 
definition of CV deaths was that of exclusion. This implies that our finding should be 
interpreted with caution. The novel findings of the UKPDS study[36, 37] of the potential 
cardio-protective effect of insulin but this has not been consistent with other clinical trials 
and recent observational studies. So, the findings of our study seem to suggest that insulin 
may have similar cardiovascular effect, compared to other non-insulin GLTs.  
Insulin showed better glycaemic control than non-insulin therapy but there was no 
statistically significant difference between both treatment groups in the proportion of 
participants achieving the target HbA1c levels (≤ 7.0 or ≤7.4%) ((≤ 53 or ≤57mmol/mol).  In a 
meta-analysis of 5 major trials comparing intensive and standard treatments, a reduction in 
HbA1c by 0.9% in the intensive arm resulted in 17% reduction in non-fatal MI and 15% 
reduction in coronary heart disease but no effect on stroke [38]. The UKPDS study showed a 
21% reduction in any diabetes-related endpoint [39] and a meta-analysis showed an 18% 
increased risk of any CVD per unit rise in HbA1c level [40]. A retrospective observational 
study using UK primary care database however have shown a U-shaped association between 
HbA1c level and mortality among insulin users,[41] implying that intensive glycaemic control 
in itself may also portend the same adverse event that it tries to avert.  
In the present study, we also observed that insulin was associated with 2.65kg weight gain 
compared to the non-insulin group. Insulin-associated weight gain has been described in 
many studies and this weight gain can be excessive, affecting cardiovascular risk factors.[42-
45] Fourteen of our included trials showed that insulin was associated with increase in 
weight compared to its comparators while in contrast, a single-arm 14-week trial of the 
PREDICTIVE study,  using insulin determir, showed no weight gain in both types 1 and 2 
diabetics[46]. This should be interpreted with caution due to the short trial duration, 
heterogeneity of the population studies and the different measures of outcomes among the 
participants. Weight gain has been shown to worsen all elements of CV risk profile—
dyslipidaemia, hypertension, insulin-resistance and elevated fibrinogen—in a continuous 
graded fashion[47, 48]. In a viscous cycle, weight-gain associated insulin resistance increases 
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the demand for exogenous insulin which in turn leads to insulin-associated weigh-gain 
which may further worsens cardiovascular risk and insulin resistance.  
This study also showed that insulin is associated with 80% increased risk of hypoglycaemia 
than the non-insulin comparator group. This is consistent with those of major clinical trials 
as the ADVANCE, UKPDS, VADT and ACCORD which showed higher (19% up to 3-fold) risks 
of hypoglycaemia following intensive glycaemic control with insulin and other GLTs.[49-53] 
Hypoglycaemia is a well-known side effect of antihyperglycaemic agents and is associated 
with sympathetic surge and release of catecholamines with resulting tachycardia, raised BP 
and other haemodynamic changes which increased risk of an atherosclerotic event.[54] This 
link is best explained by resultant increased myocardial activity, platelet-aggregation and 
activity, and haematocrit which can trigger cardiac and ischaemic events in diabetic (high-
risk) patients.[55-58] None of these studies however compared between insulin and 
sulfonylurea, the latter an important glucose lowering therapy which is known to be 
associated with an increased risk of hypoglycaemia. 
We also reported that the risk of other severe and non-severe drug-related adverse events 
was greater in the non-insulin than insulin arms. This, however, had no significant effect on 
the rate of drop outs within the individual trials. 
 
5.1. Strength and Limitations:  
This systematic review and meta-analysis derives its strength mostly from the use of only 
RCTs, the number of trials (totalling 18) and the large number of participants (19,300) 
involved, which provided enough statistical power to detect any true effect.  
One limitation of this study is inadequate blinding of participants and personnel, leading to 
the high risk of performance bias; and the non-blinding of assessors except in one trial[27] 
which led to a high risk of detection bias. As this limitation mirrors that of the included trials, 
these biases were mitigated by the fact that these outcomes (HbA1c and weight) were 
objectively assessed. Similarly, the non-standardised format of reporting the adverse events 
associated with the treatment groups could have led to either under- or over-reporting of 
events, as well as selective reporting. Other limitations include the variation in the study 
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design between the studies; the broad classification of different classes of GLTs into only 
two groups despite the variations in their mechanisms of action and effect on known CV risk 
factors; and the fact that our analysis was limited only to published literature. Finally, most 
studies failed to adequately explore the impact of some CV risk factors that might predict 
adverse CV events in the treatment groups. 
6. Conclusion: 
Insulin showed similar risk of adverse CV outcomes with non-insulin GLTs but was associated 
with superior reduction in HbA1c. Also, we showed no difference in the proportion of 
patients achieving HbA1c target between both groups but observed that weight reduction 
was more in the non-insulin group. There was a 2-fold risk of hypoglycaemia with insulin but 
adverse events were more common in the non-insulin group. In view of CV outcomes, 
further studies with well-defined distinct treatment groups in a well-powered clinical trial 
are needed. This should be in line with the current requirement by international agencies 
that new antihyperglycaemic agents not only show glucose lowering ability, but also not 
associated with clinically meaningful increases in cardiovascular events.   
These findings have implications for clinical practice. Therefore, individually-tailored holistic 
treatment strategy should be initiated, weighing the benefits of preventing microvascular 
complications and the risks of adverse cardiovascular and metabolic outcomes while 
incorporating lifestyle interventions.[59-61] 
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Legend: 
Figure 1: Flow chart of study identification and selection  
Figure 2: Forest Plot showing the risk of all-cause mortality and CV events between insulin 
and non-insulin treatment groups 
Figure 3: Forest plot for the mean change in HbA1c (%) between insulin and non-insulin 
treatment groups, stratified by the different drug classes of the non-insulin group 
Figure 4: Forest plot for the mean change in weight (Kg) between insulin and non-insulin 
treatment groups, stratified by the different drug classes of the non-insulin group 
Figure 5: Forest Plot showing the risk of hypoglycaemia in insulin vs non-insulin treatment 
groups 
Figure 6: Forest plot for the risk of adverse events between the insulin vs non-insulin 
treatment groups 
 
 
Appendix 
Figure 1: Search Terms 
Figure 2: Risk of bias summary showing authors' judgements about each risk of bias item for 
each included study. 
Figure 3. Funnel plot showing Egger‘s asymmetry test for publication bias in the trials for the 
risk of CV events. 
Figure 4: Forest Plot for the proportion attaining target HbA1c between the treatment 
groups. 
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Table 1: Baseline Characteristics of Included Trials 
 
Trial 
 
 
No† 
 
Sex¥ 
F(%) 
Population Trial drugs 
Age 
(yrs) 
Diabetes 
duration 
(yrs) 
HbA1c 
(%) 
Weight 
(Kg) 
BMI 
(Kgm-2) 
Trial 
duration 
Aschner et al 
(2012)[15] 
515 
 
49 
 
 
Insulin-naïve T2D patients  taking only 
metformin with HbA1c≥7% and <11% 
Insulin glargine 
vs 
Sitagliptin 
53.6 (8.8) 
4.5 
(1.9-8.2)* 
8.5(1.1) 
83.8 
(18.2)* 
31.1(4.9) 24wks 
Barnett et al 
(2006)[16] 
427 47 
 
T2D sulphonylurea (SU) failures with 
HbA1c 8-12%. 
Insulin NPH 
vs 
Metformin 
60.4  
(35-79)* 
9.2 
(0.5-37.3)* 
9.7 (1.1) 
80.1 
(50-136)* 
28.8 
(20-57)* 
24wks 
Barnett et al 
(2007)[21] 
138 53 
 
T2D aged  ≥30yrs on Metformin 
(MET)± SU failures with  HbA1c ≥7% 
and <11%, BMI>25 and <40kgm-2 and 
varying body weight 
Insulin glargine 
vs 
Exenatide 
54.9(0.8) 7.4(0.4) 9.0(0.1) 84.8(1.4) 31.1(0.4) 32wks 
Bunck et al 
(2009)[22] 
69 35 
 
MET-treated T2D at a stable dose for 2 
months and no other GLTs 3 months 
prior to screening.   
Insulin glargine 
Vs 
Exenatide 
58.4(1.4) 5.7(0.8) 7.6 ±0.1 92.4(2.4) 30.1 (0.6) 52wks 
D’Alessio et al 
(2014)[23] 
798 46 
 
T2D >1yr duration; HbA1c ≥7.5 and 
≤12%; BMI: 25-40kgm-2; on MET 
(≥1g/day) ± SU or Glinides or DPP-4i > 
3 months  
Insulin glargine 
vs 
Liraglutide 
57(9) 9(6) 9.0(1.1) 90.5 (16.7) 31.9(4.2) 24wks 
Davies et al 
(2009)[25] 
235 32 
 
T2D with BMI>27kgm-2 and elevated 
cardiovascular risk, inadequately 
controlled on 2-3 oral GLTs. 
Insulin glargine 
vs 
Exenatide 
56.5(9.1) 8.7(4.5) 8.65(0.7) 99.5(18.3) 34.1(5.3) 26wks 
Davies et al 
(2013)[24] 
222 34 
 
T2D adults not achieving adequate 
glycaemic control using MET or 
MET+SU 
Insulin detemir 
vs 
Exenatide 
58.5(10) 7.5(5.5) 8.36(0.9) 97.3(16.4) 33.7(4.7) 26wks 
de Wit  et al 
(2014)[34] 
50 38 
 
Insulin-users with T2D with weight gain 
≥4% following ≤16months insulin 
therapy, HbA1c: ≥6.5 and <8%. 
Insulin 
vs 
Liraglutide 
58 (9) 8(6.1) 7.4(0.7) 100(19.3) 34 (7) 26wks 
Diamant et al 
(2010)[27] 
456 47 
 
Adult T2D with suboptimum glycaemic 
control despite use of max tolerated dose 
of GLTs ≥ 3months 
Insulin glargine 
vs 
Exenatide 
58(9.5) 7.9(6) 8.3(1.1) 90.9(17.5) 32(5) 26wks 
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Diamant et al 
(2012)[26] 
467 NR 
Adult T2D who failed to maintain 
adequate glycaemic control with MET 
alone or MET+SU 
Insulin glargine 
vs 
Exenatide 
 
NR# NR 8.3 NR NR 84wks 
Diamant et al 
(2014)[28] 
510 52 
 
T2D patients treated with insulin 
glargine and MET±SU, HbA1c: 7-19% 
and BMI: 25.0kgm-2 
Insulin lispro 
vs 
Exenatide 
59.5(9.5) 
11.5 
(8-17)* 
8.3(1) 90.1(16.9) 32.5(4.7) 30wks 
DIGAMI-2 
(2011)[20] 
1253 33 
T2D patients with suspected acute 
myocardial  infarction 
Insulin (INS) 
vs 
INS +Non-INS 
GLTs 
vs 
Non-insulin GLTs 
68.3(10.9) 8.14(8.4) 7.68(1.7) NR 28.3(4.6) 
2.1 years 
(with a 
median 
follow up of 
4.1-8.1 
years) 
Dorkhan et al 
(2009)[29] 
30 34 
T2D patients with inadequate glycaemic 
control with MET+SU 
Insulin glargine 
vs 
Pioglitazone 
61.2(7.7) 10.3(6.8) 8.2(1.5) NR 31.2(5.8) 26wks 
Heine et al 
(2005)[30] 
549 44 
 
T2D patients with inadequate glycaemic 
control (HbA1c: 7-10%) with MET+SU 
Insulin glargine 
vs 
Exenatide 
58.9(9.2) 9.6(5.9) 8.3 (1.0) 87.9(17.4) 31.4(4.5) 26wks 
Matyjaszek-
Matuszek 
(2013)[31] 
80 56 
 
T2D adults (30-70yrs), stable on optimal 
doses of MET+SU ≥3months, and  
BMI:25-45kgm2 
Insulin glargine vs 
Exenatide 
60(9.0) 8.4(5.14) 7.9(0.9) 85.7(16.7) 32.5(4.82) 26wks 
ORIGIN 
(2012)[19] 
12537 35 
Outpatients with cardiovascular risk 
factors and T2D or IFG  and IGT 
Insulin 
vs 
Standard Care 
63.6(7.8) 
63.5(7.9) 
 
5.5(6.1) 
5.3(5.9) 
 
 
6.4 
(5.8-7.2)* 
 
83.3(16.8) 
83.1(17.3) 
29.8(5.2) 
29.9(5.3) 
6.2 years 
Tsimikas et al 
(2013)[32] 
458 41 
Insulin-naïve T2D (>6mths), HbA1c: 7-
11%, BMI≤40kgm-2, treated with 1-2 
non-insulin GLTs. 
Insulin degludec 
vs  
Sitagliptin 
56(10.8) 7.7(6.0) 8.9(1.0) 85(19.6) 30.4(5.2) 26wks 
Rosenstock et al 
(2006)[33] 
219 49 
 
Insulin naïve, ≥18yrs T2D without CV 
risk factors, on MET and SU 3 months 
and above 
 
Insulin glargine 
 vs  
Rosiglitazone 
55.6(11) 8.3(5.45) 8.8(1.0) NR 34.(6.7) 24wks 
*Median and Interquartile range.  #NR= Not Reported. †Population at the beginning of the trial.  ¥F= Females (Percentages approximated to the nearest whole number) 
DIGAMI-2: Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction, ORIGIN: Outcome Reduction with an Initial Glargine Intervention 
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Table 2: Trial Interventions and Outcome measures 
 
Trial Design Type Totala  Intervention 
groups 
Baseline 
antidiabetics 
Trial regime (dosage) Outcome 
measuresb Insulin                                                Comparator drug 
 
Aschner et al 
(2012)[15] 
 
Randomised, 
Open-label, 
Parallel-arm, 
Controlled trial 
 
 
515 
 
Insulin glargine (250) 
Vs 
Sitagliptin (265) 
 
 
Metformin 
 
Subcutaneous dose of  0.2 unit/kg to 
attain fasting plasma glucose of 4.0-
5.5mmol/L and increased or 
decreased by 2units respectively 
when below or above this range 
 
 
Sitagliptin 100mg daily orally.  
 
HbA1c 
Weight  
Hypoglycaemia at 
6months 
 
Barnett et al 
(2006)[16] 
 
Randomised, open-
label, parallel arm, 
Controlled trial 
Divided into two arms 
(HbA1c <9.5 and >9.5) 
before randomisation. 
 
 
427 
 
 
Insulin NPH(225) 
Vs 
Metformin(202) 
 
 
 
Sulphonylurea 
 
Inhalation (INH) in 1- and 3-mg dose 
blister packs 
 
1g twice daily 
 
Change in HbA1c 
 
Barnett et al 
(2007)[21] 
 
Randomised, 
Open-label, 
Crossover, 
Controlled trial 
 
 
138 
 
Insulin glargine (70) 
Vs 
Exenatide (68) 
 
Metformin  +/- 
Sulphonylurea 
 
Once daily at bedtime targeting a 
fasting serum glucose level  
≤5.6mmol/L for 16 weeks, then 
switch over to comparator after 
16weeks 
 
 
5µg BD for the first 4 weeks and 
10µg thereafter. Then switch over 
to comparator after 16weeks 
 
HbA1c,  
Weight 
FPG1 
 
Bunck et al 
(2009)[22] 
 
Randomised, 
Open-label, 
Parallel-arm, 
Controlled trial 
 
 
69 
 
Insulin glargine (33) 
Vs 
Exenatide (36) 
 
 
Metformin 
Initial dose of 10 IU to attain a 
glucose level of 4.5 and 5.5 mmol/L 
increased or decreased by 2 units 
when above or below this range 
respectively. 
 
Initiated dose of 5 µg BD for 4 
weeks followed by 10 µg BD, 
titrated to a max dose of 20 µg. 
 
 
B-cell function,  
HbA1c,  
Body weight  
 
D’Alessio et al 
(2014)[23] 
 
Randomised, open-
label, Parallel-arm, 
Controlled trial with a 
24-wk extension phase 
with crossover 
 
 
 
798 
 
Insulin glargine (489) 
Vs 
Liraglutide (489) 
 
 
Metformin  +/- 
Sulphonylurea 
 
Adjusted (titrated)every 3 days to 
target a fasting plasma glucose of 
4.0-5.5mmol/L 
 
0.6mg once daily increased to 
1.2mg and 1.8mg daily weekly 
according to response. 
 
HbA1c 
Weight 
Hypoglycaemia 
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Davies et al 
(2009)[25] 
Randomised, 
Open-label 
Parallel-arm, 
Controlled trial 
 
235 
Insulin glargine (117) 
Vs 
Exenatide (118) 
Metformin, 
Sulphonylurea, 
Thiazolidinedione 
 
Initial dose of 10IU/day and titrated 
weekly to target FPG level 
≤5.6mmol/L  
5µg BD for the first 4 weeks and 10 
µg BD for the remainder of the 
study. 
HbA1c 
Hypoglycaemia 
Weight 
 
Davies et al 
(2013)[24] 
 
Randomised, 
Open-label 
Parallel-arm, 
Controlled trial 
 
 
 
222 
 
 
Insulin detemir (105) 
Vs 
Exenatide (111) 
 
 
Metformin  +/- 
Sulphonylurea 
 
 
Insulin determir once or twice daily,  
titrated to FPG level <5mmol/L 
 
 
2mg subcutaneous once weekly 
-Proportion of 
achieving HbA1c 
≤7mmol/L and 
weight ≥1.0kg 
-HbA1c 
-Hypoglycaemia 
 
  
 
de Wit  et al 
(2014)[34] 
Randomised, 
Open-label 
Parallel-arm, 
Controlled trial 
 
 
50 
 
Insulin (24) 
Vs 
Liraglutide (26) 
 
Metformin  +/- 
Sulphonylurea 
 
 
Standard therapy (continuation and 
intensification of insulin therapy 
without Liraglutide)  
 
 
1.8mg/day  
 
HbA1c 
Body weight  
 
Diamant et al 
(2010)[27] 
 
Randomised  
Open-label  
Controlled non-
inferiority trial 
 
 
 
456 
 
Insulin glargine (223) 
Vs 
Exenatide (233) 
 
Metformin  +/- 
Sulphonylurea 
And others 
 
Once daily injection, starting does 
10IU, target glucose range between 
4.0-5.5 mmol/L 
 
2mg once a week injection 
 
HbA1c  
Weight gain  
 
Diamant et al 
(2012)[26] 
 
Randomised  
Open-label  
Parallel-arm, 
Controlled trial 
 
 
467 
 
Insulin glargine (234) 
Vs 
Exenatide (233) 
 
 
Metformin  +/- 
Sulphonylurea 
 
 
 
Once daily (10IU/day  
 
2mg once weekly  
 
-Proportion  of 
patients achieving 
HbA1c <7.0 
-Change in HbA1c 
 
 
Diamant et al 
(2014)[28]  
 
Randomised  
Open-label  
Controlled non-
inferiority trial 
 
 
627 
 
Insulin Lispro (312) 
Vs 
Exenatide (315) 
 
Insulin glargine  
and metformin 
 
Thrice daily meal time dose titrated 
to pre-meal glucose of 5.6-6mmol/L.  
 
5µg BD for the first 4 weeks and 
10µg thereafter.  
 
HbA1c 
Weight 
DIGAMI-2 
(2011)[20] 
Randomised  
Open-label 
Blinded evaluation trial 
(post hoc analysis) 
 
1253 
Insulin (474) 
Vs 
INS + Non-INS GLT (473) 
Vs 
Non-INS GLT (304) 
 
Not described 
 
Short-acting insulin before meals and 
intermediate/long-acting insulin in 
the evening after 24-hr infusion of 
insulin and glucose. 
 
Standard non-insulin GLTs given by 
a physician according to local 
routines after a 24-hr ins-glucose 
infusion. 
 
Risk of all-cause 
mortality and CV 
events (including 
CV death) 
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Dorkhan et al 
(2009)[29] 
 
Randomised  
Open-label  
Controlled trial 
(pilot study) 
 
 
 
30 
 
Insulin glargine (15) 
Vs 
Pioglitazone (15) 
 
 
Metformin  and 
Sulphonylurea 
 
 
Insulin was up-titrated to achieve 
fasting plasma glucose <6mmol/l 
 
Increased to 45mg/day after 16 
weeks if HbA1c>6.2% 
 
HbA1c, 
BMI 
 
 
Heine et al 
(2005)[30] 
 
Randomised  
Open-label  
Parallel-arm, 
Controlled trial 
 
 
549 
 
Insulin glargine (267) 
Vs 
Exenatide (282) 
 
 
Metformin  and 
Sulphonylurea 
 
 
1 daily dose titrated to FPG level of 
less than 5.6mmol/L (<100mg/dl)  
 
10 µg/day twice daily  
 
HbA1c, 
Weight 
 
 
Matyjaszek-
Matuszek et 
al (2013)[31] 
 
Randomised  
Open-label  
Parallel-arm, 
Controlled trial 
 
 
80 
 
Insulin glargine (40) 
Vs 
Exenatide (40) 
 
Metformin  and 
Sulphonylurea 
 
 
10IU/day  titrated  with 2IU every 3 
days (if needed) to achieve FPG 
<5.6mmol/L 
 
5µg BD for 4 weeks, later increased 
to 10µg BD for the remaining trial 
period 
 
HbA1c 
Body weight 
 
 
ORIGIN 
(2012)[19] 
 
Randomised  
Open-label 
Multi-centre trial 
 
12,537 
 
Insulin Glargine (6264) 
Vs 
Standard care (6273) 
 
Glucose-lowering 
therapies(GLTs) 
 
Insulin glargine  
 
GLTs mainly  metformin and 
sulphonylurea but never including 
Insulin glargine 
 
CV events 
(including CV 
mortality) 
Weight  
 
Philis-
Tsimikas et al 
(2013)[32] 
 
Randomised, open-
label, parallel arm, 
Controlled trial 
 
 
 
458 
 
Insulin degludec  (229) 
Vs 
Sitagliptin (229) 
 
1-2 OADs        
(only among 
metformin, SU, 
Glinides or 
Pioglitazones) 
 
 
10IU once daily titrated  (if needed) 
to achieve FPG <5.0mmol/L 
 
100mg orally once daily 
 
HbA1c 
 
Rosenstock et 
al (2006)[33] 
 
Randomised, open-
label, parallel arm, 
Controlled trial 
 
 
 
219 
 
Insulin glargine (105) 
Vs 
Rosiglitazone (112) 
 
Metformin  and 
Sulphonylurea 
 
 
10units/day for 7 days with forced 
titrated to target FPG ≤5.5-6.7 
mmol/L (≤100-120MG/dl) 
 
4mg/day. Increased to 8mg/day 
any time after 6 weeks in FPG was 
>5.5mmol/l 
 
HbA1c,  
Weight 
Hypoglycaemia  
        
aTrial no: This includes only persons randomised to a treatment group 
PG: Fasting Plasma Glucose; 
bThe list is not exhaustive. Only the outcome measures of interest were listed.  
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Table 3: Commonest reported adverse drug events in Insulin vs Non-insulin groups 
 
 
Adverse Events 
Number of Reported Events 
Insulin, n (%) Non-insulin, n (%) 
Nasopharygitis 239 (21.08) 246 (17.93) 
Influenza 68 (6.00) 68 (4.96) 
Mss/Back Pain 51 (4.50) 62 (4.52) 
Headache 156 (13.76) 202 (14.72) 
Gastrointestinal pain 37 (3.26) 108 (7.87) 
Dizziness 18 (1.59) 34 (2.48) 
Arthralgia 32 (2.82) 38 (2.77) 
Diarrhoea 99 (8.73) 229 (16.69) 
Infections-Infestations 62 (5.47) 55 (4.01) 
Hypertension/AMI 15 (1.32) 14 (1.02) 
Vomiting 36 (3.17) 177 (12.90) 
Nausea 60 (5.29) 586 (42.71) 
Constipation 25 (2.20) 67 (4.88) 
Dyspepsia 19 (1.68) 81 (5.90) 
Cough 61 (5.38) 40 (2.92) 
Reduced Appetite 12 (1.06) 79 (5.76) 
CNS Symptoms 38 (3.35) 29 (2.11) 
Injection  site reactions 4 (0.35) 64 (4.66) 
Total number of events 1134 (100) 1372 (100) 
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Appendix: Figure 1. 
 
 
These databases were electronically search using the using keywords, mesh headlines and 
terms as  
“Diabetes Mellitus, Type 2/complications"[Mesh] OR "Diabetes Mellitus, Type 2/drug 
therapy"[Mesh] AND "Diabetes Mellitus, Type 2/epidemiology"[Mesh] OR "Diabetes 
Mellitus, Type 2/mortality"[Mesh] OR "Diabetes Mellitus, Type 2/prevention and 
control"[Mesh] OR "Diabetes Mellitus, Type 2/therapy"[Mesh] AND "insulin regime" OR 
"insulin schedule" OR insulin tim* OR "insulin itinerary" OR insulin us* OR insulin dose OR 
"insulin administration" OR insulin quantit* OR "insulin shot" OR "insulin measure" AND 
“cardiovascular disease" OR "heart disease" OR macrovascular OR cardio* OR "myocardial 
infarction" OR MI OR stroke OR cerebrovascular OR cerebro* OR "major adverse 
cardiovascular event" OR "major adverse coronary event" OR MACE OR "all-cause mortality" 
AND “Randomized Controlled Trials”.  
 
 
 
 
